Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 1
Submit an article Journal homepage
356
Views
10
CrossRef citations to date
0
Altmetric
Review

Improving the safety of intravenous iron treatments for patients with chronic kidney disease

Xenophon KassianidesAcademic Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UKView further author information
,
Adil Mohammad HazaraAcademic Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UKView further author information
&
Sunil BhandariAcademic Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0996-9622View further author information
ORCID Icon
Pages 23-35 | Received 08 Sep 2020, Accepted 16 Nov 2020, Published online: 26 Nov 2020

  • McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–1510. 9
  • Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9. 1 DOI:10.1371/journal.pone.0084943
  • Wong MMY, Tu C, Li Y, et al. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2019;13:613–624. 4
  • Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease. Acta Haematol. 2019;142(1):44–50.
  • Keith DS, Nichols GA, Gullion CM, et al. Longitudinal Follow-up and Outcomes among a Population with Chronic Kidney Disease in a Large Managed Care Organization. Arch Intern Med. 2004;164(6):659–663.
  • Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019;22(6):593–604.
  • KIDGO Work Group, Kidney Disease: improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease [Internet]. Kidney Int. Suppl. 2012. [cited 2020 Sep 7]. Available from: http://kdigo.org/home/guidelines/anemia-in-ckd/%5Cnhttp://linkinghub.elsevier.com/retrieve/pii/S2157171615310777
  • NICE Guideline NG8. Chronic kidney disease: managing anemia. [Internet]. 2015 [ cited 2020Jul7]. Available from: https://www.nice.org.uk/guidance/ng8
  • Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. BioMed Central; 2017;18(1):345.
  • Bhandari S, Pereira DIA, Chappell HF, et al. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. MDPI; 2018;11(3):82.
  • Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematology. 2015;2015(1):8–13.
  • Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol. 2016;36:87–93.
  • Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92(10):1068–1078.
  • Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS One. Public Library of Science; 2015;10(2):e0117383–e0117383.
  • Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016. p. 28–39.
  • Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 2007;72:638–642.
  • Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron-in patients with chronic kidney disease. Kidney Int. 2004;65(6):2279–2289.
  • Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006;(Supplement 1):19–23. DOI:10.2215/CJN.01420406
  • Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014;12(3):296–300.
  • Garbowski MW, Bansal SS, Porter JB, et al. NTBI Is Transiently Generated from Two Compartments during a Single Dose of Intravenous Iron - a Randomized Controlled Clinical Study. Blood. 2019;134(Supplement_1): 2234–2234. DOI:10.1182/blood-2019-125618
  • Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480–491.
  • Jerschow E, Lin RY, Scaperotti MM, et al. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318–1328.
  • Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. Wolters Kluwer Health; 2016;25(6):529–535.
  • European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines the European Medicines Agency’s Committee for Medicinal Products for Human Use [Internet] 2013. [cited 2020 Sep 7]. Available from: www.ema.europa.eu
  • McCarthy JT, Regnier CE, Loebertmann CL, et al. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - A comparison of two products. Am J Nephrol. 2000;20(6):455–462.
  • Fletes R, Lazarus JM, Gage J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001;37(4):743–749.
  • Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–382.
  • Fishbane S. Safety in iron management. Am J Kidney Dis. 2003;41:18–26.
  • Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: north American clinical trial. Am J Kidney Dis. 2000;36(1):88–97.
  • Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. J Am Med Assoc. 2015;314(19):2062–2068.
  • Achebe M, DeLoughery TG. Clinical data for intravenous iron – debunking the hype around hypersensitivity. Transfusion. 2020;60:1154–1159.
  • Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2020; DOI:10.1093/ndt/gfaa011
  • Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075–2084.
  • Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30(9):1577–1589.
  • Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646–655.
  • Sivakumar C, Jubb VM, Lamplugh A, et al. Safety of intravenous Iron - Cosmofer and monofer therapy in peritoneal dialysis and Non-Dialysis-Dependent chronic kidney disease patients. Perit Dial Int. 2019;39(2):192–195.
  • Jesus-Silva JA, Lamplugh A, Dhada S, et al. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience. BMC Nephrol. 2020;21(1):212.
  • Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015;172(21):5025–5036.
  • Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
  • Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; (9572):1502–1504. DOI:10.1016/S0140-6736(07)60689-8
  • Szebeni J, Baranyi L, Sávay S, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol - Hear Circ Physiol. 2006;290(3):H1050-8.
  • Lim W, Afif W, Knowles S, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. Vox Sang. 2019;114(4):363–373.
  • Macdougall IC, Vernon K. Complement Activation-Related Pseudo-Allergy: A Fresh Look at Hypersensitivity Reactions to Intravenous Iron. Am J Nephrol. 2017;45(1):60–62.
  • Biggar P, Hahn KM. [Importance of the different i.v. iron generations for everyday medical practice]. MMW Fortschr Med. 2013;(Suppl1):18–24. DOI:10.1007/s15006-013-0732-4
  • Fütterer S, Andrusenko I, Kolb U, et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013;86:151–160.
  • Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012;7(12):e50295.
  • Florenzano P, Cipriani C, Roszko KL, et al. Approach to patients with hypophosphataemia. Lancet Diabetes Endocrinol. 2020;8(2):163–174.
  • Goodnough LT, Van Wyck DB, Mangione A, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009;49(12):2719–2728.
  • Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266–275.
  • Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: A systematic literature review. Ther Clin Risk Manag. 2020;16:245–259.
  • Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. Wiley Online Library; 2013;28(8):1793–1803.
  • Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):e124486.
  • Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. J Am Med Assoc. 2020;323(5):432–443.
  • Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018;33:1628–1635.
  • Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833–842.
  • Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis- dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599–1607.
  • Prats M, Font R, García C, et al. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: posthoc analysis of a prospective study. BMC Nephrol. 2013;14(1). DOI: 10.1186/1471-2369-14-167
  • Sari V, Atiqi R, Hoorn EJ, et al. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. Neth J Med. 2017;75:65–73.
  • Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol (Lausanne). 2018;9:1.
  • Fragkos KC, Sehgal V, Rogers J, et al. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose—Real world experience from a tertiary centre in the UK. GastroHep. 2020;2:205–214.
  • Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015 06 17. 2015;88(4):905–914.
  • Bailie GR, Larkina M, Goodkin DA, et al. Data from The dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162–168.
  • Feldman HI, Santanna J, Wensheng G, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002;13:734–744.
  • Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis. 1999;34(4):S47–S52.
  • Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007;41:1476–1480.
  • Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347(aug15 1):f4822.
  • Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017;15:422–437.
  • Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol. 2002;57(6):457–461.
  • Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23.
  • Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the pivotal trial. J Am Soc Nephrol. 2020;31(5):1118–1127.
  • Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. Oxford University Press; 2014;29(4):809–822.
  • Fell LH, Seiler-Mußler S, Sellier AB, et al. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrol Dial Transplant. 2016;31(11):1835–1845.
  • Brookhart MA, Freburger JK, Ellis AR, et al. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am J Kidney Dis. 2016;67(1):119–127.
  • Li X, Cole SR, Kshirsagar AV, et al. Safety of dynamic intravenous iron administration strategies in hemodialysis patients. Clin J Am Soc Nephrol. 2019;14(5):728–737.
  • Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151–1158.
  • Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol. Am Soc Nephrol; 2015;10(10):1799–1805.
  • Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;(3): 457–467. DOI:10.2215/CJN.05390517
  • Aly SS, Fayed HM, Ismail AM, et al. Assessment of peripheral blood lymphocyte subsets in children with iron deficiency anemia. BMC Pediatr 2018;18(1):49.
  • Jiang Y, Li C, Wu Q, et al. Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. Nat Commun. 2019;10(1). DOI:10.1038/s41467-019-11002-5
  • Jonker FAM, Boele van Hensbroek M. Anaemia, iron deficiency and susceptibility to infections. J Infect. 2014;69:S23–7.
  • Ganz T, Aronoff GR, Gaillard CAJM, et al. Iron administration, infection, and anemia management in ckd: untangling the effects of intravenous iron therapy on immunity and infection risk. Kidney Med. 2020;2(3):341–353.
  • Zager RA, Johnson ACM, Hanson SY, et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40(1):90–103.
  • Johnson ACM, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol - Ren Physiol. 2010;299(2):F426-F435.
  • Bresgen N, Eckl PM. Oxidative stress and the homeodynamics of iron metabolism. Biomolecules. 2015;5(2):808–847.
  • Zager RA, Johnson ACM, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. Elsevier; 2004;66(1):144–156.
  • Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458.
  • Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070–3080.
  • Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013;8(11). DOI:10.1371/journal.pone.0078930
  • Kassianides X, Zeidan A, Bhandari S. So051Prospective open-label explorative randomised single centre comparative study to determine the effects of various intravenous iron preparations on haemoglobin, haemetenics, markers of kidney function, quality of life and safety. Nephrol Dial Transplant. 2020;35(Supplement_3).
  • Kassianides X, Zeidan A, Sturmey R, et al. P0848Prospective open-label explorative randomised single-centre comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (Iron-Ckd). Nephrol Dial Transplant. 2020;35(Supplement_3).
  • Nuhu F, Seymour AM, Bhandari S. Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. Antioxidants. 2019;8(10):498.
  • Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29(2):255–259.
  • Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis- stimulating agents: a MRI study. Am J Med. 2012;125(10):991–999.
  • Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18(3):975–984.
  • van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. 2020;16:77–98.
  • Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol. 2012;89(3):187–197.
  • Bhandari S, Daar S. Deferasirox and renal dysfunction in children. Pediatr Nephrol. 2012;27(11):2159.
  • Piga A, Roggero S, Salussolia I, et al. Deferiprone. Ann N Y Acad Sci. 2010;1202(1):75–78.
  • Wish JB, Aronoff GR, Bacon BR, et al. Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol. 2018;47(2):72–83.
  • Rostoker G, Vaziri ND, Fishbane S. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century. Drugs. 2016;76(7):741–757.
  • Ramanathan G, Olynyk JK, Ferrari P. Diagnosing and preventing iron overload. Hemodial Int. 2017;21:S58–67.
  • Beshara S, Sörensen J, Lubberink M, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol [Internet]. 2003;120(5):853–859. Available from: https://pubmed.ncbi.nlm.nih.gov/12614222/
  • Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3:12–33.
  • Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107(1):16–30.
  • Monofer 100mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [ cited 2020 Sep 7]. Available from: https://www.medicines.org.uk/EMC/medicine/23669/SPC/Monofer+100mg+ml+solution+for+injection+infusion/#gref
  • Ferinject (ferric carboxymaltose) - summary of product characteristics (SmPC) - (emc) [Internet]. [ cited 2020 Sep 7]. Available from: https://www.medicines.org.uk/emc/product/5910/smpc#gref
  • Kang H, Han M, Xue J, et al. Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019;10(1):5134.
  • Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(4):272–291.
  • Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815-826.
  • Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(5):331–338.
  • Li Z-L, Tu Y, Liu B-C. treatment of renal anemia with roxadustat: advantages and achievement. Kidney Dis. 2020;6(2):65–73.
  • Bhandari S, Naudeer S. Improving efficiency and value in health care - intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract. 2008;14(6):996–1001.
  • Zeidan A, Bhandari S. Anemia in peritoneal dialysis patients; iron repletion, current and future therapies. Perit Dial Int. 2017;37(1):6–13.
  • von Haehling S, Ebner N, Evertz R, et al. Iron deficiency in heart failure: an overview. JACC Hear Fail. 2019;7(1):36–46.
  • Kassianides X, Ziedan A, Allgar V, et al. P0858A Multicentre prospective double blind randomised controlled trial of intravenous iron in iron deficient but not anaemic patients with chronic kidney disease on functional status. Nephrol Dial Transplant. 2020. DOI:10.1093/ndt/gfaa142.P0858
  • Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668.
  • Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. Circulation. 2017;(15):1374–1383. DOI:10.1161/CIRCULATIONAHA.117.027497
  • Charles-Edwards G, Amaral N, Sleigh A, et al. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients with Chronic Heart Failure and Iron Deficiency: FERRIC-HF II Randomized Mechanistic Trial. Circulation. 2019;139(21):2386–2398.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.